Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Search
Meet BIs Brains Michael Sand
Dr. Michael Sand, Senior Clinical Program Leader, CNS at Boehringer Ingelheim shares his view on the complexities of the CNS research landscape.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
Life stages of cats
Cats go through different stages of life. Knowing more about these stages can help you understand your cat’s medical needs better.
“LastMile” – improving through digital
“LastMile” – improving through digital
Winners of 2020 BVDzero Case Awards announced
Winners of 2020 BVDzero Case Awards announced
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Our Approach
We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
Introducing Karl and Klara Kidney
Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
COVID-19 Q&A for people with diabetes
COVID-19 Q&A for people with diabetes
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
CENTRAGARD internal parasite protection for cats in US
Centragard, an innovative product to treat heartworm disease in cats, launched in the U.S.
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
1990-2022: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2022, with milestones
Taking cancer on with smart combinations
Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition
Empowering all employees
Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession